Table 1. Summary of HPV genotypic detection and p16 IHC in our HNSCC cohort.
| Sites of cancer (N = 159) | HPV (%) | HPV 16 | HPV 18 | HPV 31 | HPV 45 | HPV 56 | HPV 68 | P16 |
|---|---|---|---|---|---|---|---|---|
| Oral cavity/% (n = 52) |
48 (92.3) |
0 | 9 (17.3) |
44 (84.6) |
48 (92.3) |
6 (11.5) |
26 (50) |
2 (3.8) |
| Oropharynx/% (n = 31) |
29 (93.5) |
6 (19.4) |
4 (12.9) |
22 (71.0) |
25 (80.6) |
6 (19.4) |
11 (35.5) |
14 (45.2) |
| Larynx/% (n = 52) |
46 (88.5) |
2 (3.8) |
8 (15.4) |
41 (78.8) |
45 (86.5) |
9 (17.3) |
27 (51.9) |
1 (1.9) |
| Hypopharynx/% (n = 13) |
11 (84.6) |
0 | 2 (15.4) |
9 (69.2) |
11 (84.6) |
1 (7.7) |
6 (46.2) |
0 |
| Others/% (n =11) |
10 (90.9) |
0 | 1 (9.1) |
10 (90.9) |
10 (90.9) |
2 (18.2) |
8 (72.7) |
2 (18.2) |
| 144 (90.6) |
8 (5.0) |
24 (15.1) |
126 (79.2) |
139 (87.4) |
24 (15.1) |
78 (49.1) |
19 (11.9) |